Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.

摘要: There is a multitude of assays for the detection circulating tumor cells (CTCs) but very limited number studies comparing clinical relevance results obtained with different test methods. The DETECT trial metastatic breast cancer patients was designed to directly compare prognostic impact two commercially available CTC that are prominent representatives immunocytochemical and RT-PCR based technologies. In total, 254 were enrolled in this prospective multicenter trial. CTCs assessed using both AdnaTest Breast Cancer CellSearch system according manufacturers' instructions. With system, 116 221 (50%) evaluable CTC-positive on cut-off level at 5 or more CTCs. median overall survival (OS) 18.1 months patients. (95%-CI: 15.1-22.1 months) compared 27 CTC-negative (23.5-30.7 months; p<0.001). This OS also significant subgroups triple negative, HER2-positive hormone receptor-positive/HER2-negative primary tumors. progression free (PFS) not correlated status our cohort receiving types lines systemic treatment (p = 0.197). multivariate analysis, presence an independent predictor (HR: 2.7, 95%-CI: 1.6-4.2). When performed, 88 (40%) CTC-positive. CTC-positivity by had no association PFS OS. depends method. present indicate superior predicting outcome advanced cancer. Current Controlled Trials Registry ISRCTN59722891 .